



SPAFID
CONNECT

Informazione Regolamentata n. 0957-16-2022	Data/Ora Ricezione 08 Aprile 2022 09:51:02	Euronext Milan
--	---	----------------

Societa' : DiaSorin
Identificativo : 160097
Informazione
Regolamentata
Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone
Tipologia : REGEM
Data/Ora Ricezione : 08 Aprile 2022 09:51:02
Data/Ora Inizio : 08 Aprile 2022 09:51:03
Diffusione presunta
Oggetto : Update Annual Calendar of Corporate
Events 2022

Testo del comunicato

Please see the attachment.

DIASORIN S.P.A. – UPDATE 2022 ANNUAL CALENDAR OF CORPORATE EVENTS*

Saluggia, April 8, 2022 – Partially updating the notice submitted on December 21, 2021, please find below the annual calendar of corporate events, including the new scheduled date for approval of the interim financial statements related to the first quarter 2022.

Board of Directors

May 6, 2022	First Quarter 2022 results approval
July 29, 2022	Half-Yearly Financial Report approval
November 10, 2022	Third Quarter 2022 results approval

Shareholders' Meeting

April 29, 2022	Annual General Meeting for: (i) Statutory Financial Statements 2021 approval; (ii) Report on the remuneration policy and fees paid approval; (iii) election of corporate bodies.
-----------------------	---

* Indicative dates subject to change. Any changes will be communicated without delay.

In addition, the Company notifies that the month envisaged for the payment of any dividend in relation to 2021 results is May 2022. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana S.p.A. regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at www.diasoringroup.com

Fine Comunicato n.0957-16

Numero di Pagine: 3